Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Liver diseases with pregnancy


Related Books

Free with a 30 day trial from Scribd

See all

Related Audiobooks

Free with a 30 day trial from Scribd

See all
  • Be the first to comment

Liver diseases with pregnancy

  1. 1. LIVER DISEASES WITH PREGNANCY Dr. Mohammed Abdallah
  2. 2. physiology • Spider angioma and palmar erythema, which are typical clinical markers of liver disease, are commonly seen during pregnancy as a consequence of the hyperestrogenic state. • Gall bladder motility is decreased, increasing the incidence of cholelithiasis in pregnant women • decreased albumin in all trimesters due to hemodilution, and the decline in albumin levels becomes more pronounced as pregnancy advances. • Alkaline phosphatase (ALP) is increased in the third trimester, but it is of placental origin due to fetal bone development. • Alpha fetoprotein (AFP) levels also increase because it is produced by the fetal liver. • In contrast, other liver biochemical tests, remain within the normal range during normal pregnancy. such as total bile acids concentration, serum alanine transaminase (ALT or SGPT) aspartate transaminase, (AST or SGOT) gamma-glutamyl transpeptidase (GGT), and bilirubin,
  3. 3. • Pregnancy is a pro-coagulant state in which clotting factors (I, II, V, VII, X, and XII) and fibrinogen are increased . • whereas the ranges for prothrombin time (PT) and activated partial thromboplastin (APT) time are within normal values . physiology
  4. 4. LIVER FUNCTION TESTS • Alanine aminotransferase (ALT) – an enzyme found mainly in the liver; best test to detect hepatitis • Alkaline phosphatase (ALP) – an enzyme related to the bile ducts; often increased if ducts are blocked • Aspartate aminotransferase (AST) – an enzyme found in the liver and a few other places, particularly the heart and other muscles • Gamma-glutamyl transferase (GGT) – an enzyme found mainly in the liver; very sensitive to changes in liver status, especially when bile ducts are blocked • Total bilirubin – measures all of the bilirubin in the blood; levels are increased with many liver diseases and other conditions, such as hemolysis, that lead to increased production of bilirubin • Direct bilirubin – measures a form of bilirubin that is conjugated (combined with another compound) in the liver; only increased in liver disease • Albumin – measures albumin, the main protein made by the liver, and tells how well the liver is making it • Total protein – measures albumin and all other proteins in blood, including antibodies present to help fight off infections (antibodies are not made in the liver) • Lactate dehydrogenase (LD or LDH) – an enzyme released with tissue damage; may be elevated with acute liver disease
  5. 5. physiology • aspartate aminotransferase (AST) • and alanine aminotransferase (ALT) evaluate Liver cell injury or necrosis • albumin level • prothrombin time evaluate liver synthetic function (are depressed in cirrhosis or severe acute liver disease) • alkaline phosphatase, • bilirubin, • gamma glutamyl transpeptidase evaluate Cholestasis and biliary obstruction
  6. 6. Liver diseases with pregnancy coincidental liver disease • hepatitis • Gallstones • Drug toxicity . underlying chronic liver disease. pregnancy-related 1. The preeclampsia- associated liver diseases • (HELLP) syndrome • (AFLP) acute fatty liver of pregnancy 2. Not preeclampsia- associated liver diseases • Hyperemesis gravdarum • (ICP) intrahepatic cholestasis of pregnancy
  7. 7. Hyperemesis gravidarum • is intractable, dehydrating vomiting in the first trimester of pregnancy; 50% of patients with this condition have abnormal liver test have been shown to be risk factors for HG development • Multiple gestations • increased body mass index (BMI) • pre-existing diabetes • psychiatric illness • and HG in a previous pregnancy .
  8. 8. • Elevations in serum aminotransferases usually go up to 200 U/L and this is the most common abnormal liver test result. • In pregnant women presenting with abnormal liver enzymes with or without HG in the first trimester, other causes of abnormal liver enzymes must be ruled out . Hyperemesis gravidarum
  9. 9. • Initial management is conservative • The only FDA-approved drug for treating nausea and vomiting in pregnancy is doxylamine/pyridoxine ( VIT B6) . • Ginger may be used as a nonpharmacologic option, as it has had some beneficial effects in the treatment of nausea and vomiting of pregnancy. • However, antihistamines, antiemetics of the phenothiazine class, and promotility agents (eg, metoclopramide) are used • In refractory cases, ondansetron ( zofran) and steroids may be considered Hyperemesis gravidarum
  10. 10. • Obstetric cholestasis is diagnosed when otherwise unexplained pruritus occurs in pregnancy and abnormal liver function tests (LFTs) and/or raised bile acids occur in the pregnant woman and both resolve after delivery. • Pruritus that involves the palms and soles of the feet is particularly suggestive • Other evidence of cholestasis should be sought, including pale stool, dark urine and jaundice, and other risk factors identified such as a personal or family history of obstetric cholestasis, multiple pregnancy, carriage of hepatitis C and presence of gallstones. Intrahepatic cholestasis of pregnancy
  11. 11. • ICP is the most common cause of jaundice during pregnancy characterized by a reversible cholestatic condition that usually occurs during the late second and third trimester, when serum concentrations of estrogen reach their peak; it has a higher incidence in twin pregnancies, which have higher estrogen levels, and resolves after delivery, when sex hormone levels fall • ICP has rapid postnatal resolution, with signs and symptoms usually disappearing spontaneously within 6 weeks of delivery. Intrahepatic cholestasis of pregnancy
  12. 12. • The main symptom of ICP is pruritus, which typically predominates on the palms and soles of the feet and worsens at night. • Pruritus often develops after 25 weeks of gestation, with 80% of cases occurring after the 30th week. • Other symptoms of ICP can include steatorrhea, malabsorption of fat- soluble vitamins, and weight loss due to cholestasis . • Jaundice has an incidence of 14–25% and may develop 1 to 4 weeks after the onset of pruritus, with dark urine and pale feces in some women. • The most important biochemical test in the context of ICP is total bile acids concentration, greater than 10 μmol /L which can be the first, and sometimes only, laboratory abnormality • Serum bile acid values may fluctuate and increase with advancing pregnancy; therefore, it is advisable to check it weekly in women with ICP • >40 μmol serum bile acids in severe ICP is currently considered to be associated with adverse pregnancy outcomes Intrahepatic cholestasis of pregnancy
  13. 13. • Ursodeoxycholic acid improves clinical symptoms and liver parameters in a number of cholestatic liver disorders. • UDCA at a daily dose ranging from 600-2000 mg or 15 mg/kg per day was effective at reducing pruritus, decreasing the total serum bile acid levels, ALT values, and bilirubin levels and allowing delivery closer to term • Antihistamines are commonly administered in conjunction with UDCA to alleviate pruritus symptoms. • Dexamethasone should not be first-line therapy for treatment of obstetric cholestasis, • Other medications, such as cholestyramine and S-adenosyl-methionine, have not had satisfactory results Intrahepatic cholestasis of pregnancy
  14. 14. • where the prothrombin time is prolonged, the use of water- soluble vitamin K (menadiol sodium phosphate) in doses of 5–10 mg daily is indicated. • when prothrombin time is normal, water-soluble vitamin K (menadiol sodium phosphate) in low doses should be used . Intrahepatic cholestasis of pregnancy
  15. 15. Mortality/Morbidity • From a maternal viewpoint, the main consideration is intense pruritus, It is characterized by profound itching often beginning with the palms of the hands and soles of the feet without evidence of a rash which may become so intolerable that delivery is considered as early as 35-37 weeks • The fetal viewpoint is more concerning, as even with modern treatment the risk for fetal demise can range from 2-11 %. One of the more worrisome aspects of ICP is the possibility of sudden fetal death, sometimes within hours of normal fetal heart rate tracings Intrahepatic cholestasis of pregnancy
  16. 16. • Poor outcome cannot currently be predicted by biochemical results and delivery decisions should not be based on results alone. • No specific method of antenatal fetal monitoring for the prediction of fetal death can be recommended. • Ultrasound and cardiotocography are not reliable methods for preventing fetal death in obstetric cholestasis Intrahepatic cholestasis of pregnancy
  17. 17. Delivery is commonly recommended at 37 weeks’ without an amniocentesis for fetal lung maturity due to increased risk of fetal mortality and morbidity . • A discussion should take place with women regarding induction of labour after 37+0 weeks of gestation. • Women should be informed of the increased risk of perinatal morbidity from early intervention (after 37+0 weeks of gestation). • Women should be informed that the case for intervention (after 37+0 weeks of gestation) may be stronger in those with more severe biochemical abnormality (transaminases and bile acids). • Women should be informed of the increased risk of maternal morbidity from intervention at 37+0 weeks of gestation. • Women should be informed of the inability to predict stillbirth if the pregnancy continues. Intrahepatic cholestasis of pregnancy
  18. 18. • AFLP is a microvesicular fatty infiltration of hepatocytes due to Defect in beta- oxidation of fatty acids in mitochondria, leads to fat droplets formation in hepatocyte that is also known as acute yellow atrophy or acute fatty metamorphosis . • AFLP is a medical and obstetric emergency because it can be fatal for both the mother and fetus in the absence of early recognition and appropriate management . • AFLP is a rare condition, usually occurring in the third trimester, with an approximate incidence of 1: 7000 to 1: 16000 and is commonly associated (or complicated ) with preeclampsia (50 to 100 percent). Acute fatty liver of pregnancy
  19. 19. • AFLP usually occurs in the third trimester, rarely before the 30th gestational week, but up to 20% of cases present postnatally . • Clinical presentation is variable and includes non-specific symptoms such as nausea, vomiting, abdominal pain, headache, and malaise. • The clinical course can rapidly progress to acute liver failure and its complications, such as encephalopathy, jaundice, and coagulopathy Acute fatty liver of pregnancy
  20. 20. • Laboratory tests can show abnormal liver values, including:  elevated aminotransferase levels (from mild elevation to 1000 IU/L, but usually 300–500 IU/mL) .  hyperbilirubinemia (frequently >5 mg/dL).  leukocytosis, normochromic anemia, and thrombocytopenia are present, as well as hypoalbuminemia, elevated uric acid, renal dysfunction, metabolic acidosis, hyperammonemia, and biochemical pancreatitis. Ketonuria and proteinuria can be present.  Hypoglycemia is characteristic and predicts a poor prognosis.  In severe cases, prolonged PT and reduced fibrinogen levels may be found, whereas disseminated intravascular coagulation (DIK) is seen in approximately 10% of patients with AFLP. Acute fatty liver of pregnancy
  21. 21. Fifteen years ago, Ch’ng et al.published a study in which they proposed diagnostic criteria, known as the Swansea criteria, for the diagnosis of AFLP. Acute fatty liver of pregnancy
  22. 22. Swansea criteria he presence of ≥6 abnormal variables had positive predictive value of 85 percent and negative predictive value of 100 percent for finding microvesicular steatosis ●Vomiting ●Abdominal pain ●Polydipsia/polyuria ●Encephalopathy ●Elevated bilirubin (>0.8 mg/dL or >14 micromol/L) ●Hypoglycemia (<72 mg/dL or <4 mmol/L) ●Leukocytosis (>11,000 cells/microL) ●Elevated transaminases (AST or ALT) (>42 international unit/L) ●Elevated ammonia (>47 micromol/L) ●Elevated uric acid (5.7 mg/dL or >340 micromol/L) ●Acute kidney injury, or creatinine 1.7 mg/dL or >150 micromol/L ●Coagulopathy or prothrombin time >14 seconds ●Ascites or bright liver on ultrasound scan ●Microvesicular steatosis on liver biopsy The criteria are intended for use in women without hemolysis, elevated liver enzymes, and a low platelet count syndrome or preeclampsia, which limits their clinical utility
  23. 23. • The main differential diagnosis is HELLP syndrome due to the great overlap between AFLP and HELLP syndrome. Thus, distinguishing between these 2 disorders is often very difficult, potentially delaying diagnosis. • Early recognition of the disease and delivery of the fetus regardless of gestational age are the keys to successful management, Acute fatty liver of pregnancy
  24. 24. • itself is the commonest cause of hepatic tenderness and liver dysfunction in pregnancy, and 2%-12% of cases are further complicated by hemolysis (H), elevated liver tests (EL), and low platelet count (LP)- • the HELLP syndrome. Immediate delivery is the only definitive therapy, but many maternal complications can occur, including abruptio placentae, renal failure, subcapsular hematomas, and hepatic rupture. SEVER PREECLAMPSIA “ HELLP ”
  25. 25. • preeclampsia is a multisystem disorder defined by de novo hypertension after the 20th week of pregnancy with blood pressure (BP) ≥140/90 mmHg and proteinuria of >300 mg/day in association with other organ dysfunction of the mother, such as renal impairment, liver involvement, neurological or hematological complications, and uteroplacental dysfunction, as well as fetal growth restriction . • The main feature that distinguishes eclampsia from preeclampsia is the presence of seizures SEVER PREECLAMPSIA “ HELLP ”
  26. 26. • The diagnosis of HELLP syndrome is based mainly on clinical features. Women often present with fluctuating colic-like pain in the upper abdomen, usually epigastric or in the right upper quadrant. In addition, non-specific symptoms such as nausea, vomiting, and malaise are often present. • Arterial hypertension and proteinuria are noted in most women. Due to microangiopathic hemolytic anemia, • unconjugated bilirubin and LDH are increased, • whereas liver enzymes are moderately elevated (ALT 2–30 fold). Low haptoglobin may be used as another parameter for the diagnosis of hemolysis. SEVER PREECLAMPSIA “ HELLP ”
  27. 27. there are 2 classifications of HELLP syndrome: the Tennessee , and Mississippi classifications, SEVER PREECLAMPSIA “ HELLP ”
  28. 28. The Tennessee classification of HELLP The Tennessee classification describes HELLP as either complete or partial. Complete HELLP syndrome is characterized by the following: • Platelet count of 100,000/μL or less • AST or ALT levels of 70 IU/L or more • LDH (or bilirubin) (with hemolysis as evidenced on abnormal peripheral smear) levels of 600 IU/L (≥0.2 mg/dL) or more Partial HELLP syndrome is characterized by severe preeclampsia plus one of the following: • ELLP: Elevated liver enzyme levels, thrombocytopenia, no hemolysis • EL: Mildly elevated liver enzyme levels, no thrombocytopenia, no hemolysis • LP: Thrombocytopenia, no hemolysis, normal liver enzyme levels • HEL: Hemolysis, liver dysfunction, no thrombocytopenia
  29. 29. The Mississippi classification OF HELLP The Mississippi classification divides HELLP syndrome into 3 classes based on platelet count, AST or ALT levels, and LDH levels.  Class 1, which has an approximately 13% incidence of bleeding, is associated with the highest maternal morbidity and mortality rates and longest recovery time. Patients in this class have a platelet count less than 50,000/µL, liver dysfunction with AST or ALT levels greater than 70 IU/L, and hemolysis as evidenced by an LDH level greater than 600 IU/L.  Class 2 includes platelet counts from 50,000-100,000/µL with AST, ALT, and LDH levels similar to those in class 1. Class 2 has an 8% incidence of bleeding.  class 3 The mild form of HELLP has a platelet count from 100,000- 150,000/µL, AST and ALT greater than 40 IU/L, and LDH greater than 600 IU/L, with no increased risk of bleeding.
  30. 30. The Mississippi classification OF HELLP
  31. 31. Abdominal imaging methods, such as ultrasonography, CT, and MRI, should be performed in all women with HELLP syndrome in order to investigate liver complications, such as liver infarction, intraparenchymal hemorrhage, subcapsular hematoma, and hepatic rupture SEVER PREECLAMPSIA “ HELLP ”
  32. 32. As mentioned, HELLP syndrome and AFLP share similar presentations. The differential diagnosis among AFLP and HELLP syndrome is shown in Table
  33. 33. • A pregnant patient presenting with abnormal liver tests should undergo standard workup as with any non-pregnant individual . • Imaging in pregnancy Ultrasound is safe and the preferred imaging modality used in assessment of abnormal liver tests suggestive of biliary tract disease • Magnetic resonance imaging without gadolinium can be used in the second and third trimester . • Computed tomography scans carry a risk of teratogenesis and childhood hematologic malignancies but may be used judiciously with minimized radiation protocols (2–5 rads). • Endoscopy in pregnancy Endoscopy is safe in pregnancy but should be deferred until the second trimester if possible . • Meperidine and propofol can be used for endoscopic. Take home
  34. 34. • Active–passive immunoprophylaxis with hepatitis B immunoglobulin and the HBV vaccination series should be administered to all infants born to HBV-infected mothers to prevent perinatal transmission . • Women chronically infected with HBV and high viral load (>10 6 log copies/ml (200,000 IU/ml) and higher) should be offered antiviral medication with tenofovir or telbivudine in the third trimester to reduce perinatal transmission of HBV • C-section should not be performed electively in HBV-positive mothers to prevent fetal infection . • Women chronically infected with HBV should be allowed to breastfeed as recommended for infant health Take home
  35. 35. Take home All pregnancy related liver diseases that occur in late second trimester or third trimester either preeclampsia associated ( HELLP or AFLP ) OR not preeclampsia associated ( ICP) necessitate termination of pregnancy , irrespective of fetal maturity in HELLP , AFLP and in ICP if bile acids level is > 40 micromole/ L

    Be the first to comment

    Login to see the comments

  • ssuserf711be

    Dec. 3, 2019
  • aliwaleed1977

    Dec. 3, 2019
  • MohammedAbdalla

    Dec. 3, 2019
  • MohammedMaged3

    Dec. 3, 2019
  • kanthiudaya

    Apr. 7, 2020



Total views


On Slideshare


From embeds


Number of embeds